An observational study in Aneurysm, Brain, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Intracranial Aneurysm with a site in Switzerland — 8 open to participants now, 9 under way, none of them phase 3. Intracranial Aneurysm · Switzerland.
Among the 21 studies in Intracranial Aneurysm with a site in Switzerland, this one is the 12th largest by planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2023, is one of 17 observational ones, and was the 20th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →8 of the 21 studies in Intracranial Aneurysm with a site in Switzerland are open now. Recruiting first, the newest first:
Phenox GmbH · Sites in Switzerland, France, Germany and 2 more countries
Medical University of South Carolina · Sites in Switzerland, United States, Canada and 6 more countries
Ages 1–120
Nantes University Hospital · Sites in Switzerland, France, Netherlands
Ages 18+
Medtronic Neurovascular Clinical Affairs · Sites in Switzerland, Argentina, Australia and 21 more countries
Ages 18+
University Hospital, Geneva · Sites in Switzerland, United States, Canada and 8 more countries
Ages 18+ · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 300 is above the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.
Median enrollment 79 across the 4 interventional studies, 572 across the 17 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 1 study filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Intracranial Aneurysm with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this international, multicenter, mixed retrospective-prospective, exploratory, observational study is to establish an international registry to fill the knowledge gap created by the rarity of lenticulostriate and basilar perforator aneurysms and the resulting lack of knowledge about their natural history, diagnostic evaluation, management, and clinical outcomes. Specifically, comparative analyses of outcomes in patients with intracranial perforator aneurysms treated conservatively, endovascularly, and surgically will be performed. The study will also evaluate the size and location of lenticulostriate and basilar intracranial perforator aneurysms, collect information on the specific type of endovascular treatment used, compare patients with predominantly perimesencephalic subarachnoid hemorrhage (SAH) who have a perforator aneurysm to those without, and evaluate spontaneous occlusion in conservatively treated aneurysms. Core lab analysis of these aneurysms on various imaging modalities will be performed at the Inselspital and changes in aneurysm characteristics over time will be documented. In addition, the relationship between baseline characteristics and aneurysm characteristics on the incidence of hemorrhage will be examined. The study will involve approximately 20-30 centers worldwide with an estimated total sample size of 200-300 patients by 2025.
Background and current state of research
Lenticulostriate and basilar perforator aneurysms are extremely rare subtypes of intracranial aneurysms. Recent years have seen an increase in their diagnosis due to advancements in imaging technology. However, their low incidence has left a significant gap in the understanding of their natural history, diagnostic evaluation, management, and clinical outcomes. To date, the available literature consists mainly of case reports or small case series, with only a limited number of systematic reviews, such as those on lenticulostriate aneurysms (112 cases) and basilar perforator aneurysms (54 patients).
The most common presentation of perforator aneurysms is rupture, although unruptured aneurysms may be diagnosed as an incidental finding or as the cause of compressive symptoms. Initial angiography fails to identify approximately 30%-60% of perforator aneurysms. Various treatment approaches have been reported, including surgery and various endovascular techniques such as coiling, embolization with liquid embolic agents, flow-diverters, and even electrothrombosis with a microguidewire. However, all invasive strategies have inherent periprocedural risks that must be carefully weighed against the reported overall high rate of favorable outcomes in conservatively managed patients.
Despite the growing interest and knowledge in this field, an international multicenter registry that includes baseline patient characteristics, imaging, follow-up protocols, treatment strategies, and outcomes for both ruptured and unruptured intracranial perforator aneurysms is still lacking.
Research questions, hypotheses and aims
The research questions of this exploratory study are:
Methods
3.1 Study population
This is an international, multicenter, mixed-retrospective-prospective exploratory observational study.
So far, in Switzerland, the Inselspital, the University Hospital Basel, the University Hospital Lausanne, the Regional Hospital of Lugano and the Cantonal Hospital St. Gallen are participating in this study and have received ethical approval. In addition, since the start of the study in early November 2023, already 15 international centers have expressed their interest in participating. More centers worldwide will be contacted via a distribution list [European Society of Minimally Invasive Neurological Therapy (ESMINT); Society of Neurointerventional Surgery (SNIS)] and invited to participate. The investigators estimate that approximately 20-30 centers worldwide will participate with an estimated total sample size of 200-300 patients by 2025. The analysis will be based on a survey (see below for included data) specifically designed for this study and completed by local neuroradiologists, neurologists or neurosurgeons involved in the management of intracranial perforator aneurysms. The primary treating physician will review the clinical records of patients with intracranial perforator aneurysms treated conservatively, endovascularly, or surgically. Study lead and coordination as well as radiological and statistical analysis will be performed by the team at the Inselspital, Bern, Switzerland.
3.2 Baseline characteristics, imaging variables, treatment variables, and outcome variables
Data include:
Clinical endpoints include:
Safety endpoints include:
Efficacy Endpoint
3.3 Data transfer and storage (Medical-Blocks® and REDCap)
Imaging data from all external participating centers will be securely transferred via and stored on Medical-Blocks® (https://mb-neuro.medical-blocks.ch). This cloud-based platform for storage, anonymization and exchange of medical images in the neuro field (MB-Neuro) is provided by the Inselspital Bern. The platform provides the necessary interfaces to communicate with other secure and advanced IT environments via various Application Programming Interfaces (APIs). Secure Sockets Layers (SSL) with 256-bit encryption is used, which complies with the regulations of KlinV. (Verordnung über klinische Versuche) Art. 18 and HFV (Humanforschungsverordnung) Art. 5 of the Swiss Ordinance on the Storage of Health-Related Personal Data and Biological Materials. The clinical datasets will be provided in an anonymized fashion (matching the anonymized imaging data) by the physician primarily involved in patient management from the participating centers and entered and stored in REDCap.
This is an exploratory study. The investigators estimate that approximately 20-30 centers worldwide will participate with an estimated total sample size of 200-300 patients.
Categorical variables will be presented as numbers and percentages, and continuous variables as medians, interquartile range (IQR). Fisher's exact will be used for categorical and Mann-Whitney U test or Kruskal-Wallis test for continuous variables. Logistic regression results will be displayed as odds ratios (OR) for simple regression or adjusted OR (aOR) for multinomial regression analyses, with their corresponding 95% confidence intervals (CIs). As this is an exploratory study, no conclusions about significance can be drawn. Therefore, a p-value \< 0.05 will be interpreted as a trend. All analyses will be performed using established statistic software, including R 4.01 or newer, Python 3.83 or newer, Stata 16 and/or Statistical Package for the Social Sciences (SPSS) 27.00 or newer.
Patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
mRS at 3 months after initial diagnosis of an intracranial perforator aneurysm
Time frame: 90 days
mRS at last follow-up (including time-point of last follow-up after diagnosis)
Time frame: Last follow-up, expected to be on average 2 years
Rupture/re-rupture of the index aneurysm as a time-event outcome
Time frame: Date of rupture/re-rupture
Death during the acute hospital stay
Time frame: Until patient discharge, up to 4 weeks
Death up to 90 days (related to the index aneurysm)
Time frame: 90 days
Number of participants with ischemic stroke (imaging based)
Time frame: Follow-up, expected to be up to 7 days
Periprocedural and postprocedural complications in patients submitted to endovascular or surgical treatment
Time frame: Peri-/postprocedural, expected to be up to 24 hours
For patients receiving treatment, assessment of aneurysm occlusion after treatment and available follow-ups
Time frame: First follow-up, expected to be within 7 days
Plan to share: No
Started Nov 2023 (actual). Primary completion is estimated for Dec 2025, 25 months after the start.
Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 25 months is below that.
Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →